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a b s t r a c t
Triple-negative breast cancer (TNBC), especially the subset with a basal phenotype, represents the most aggressive subtype of breast cancer. Unlike other solid tumors, TNBCs harbor a low number of driver mutations. Conversely, we and others have demonstrated a signiﬁcant impact of epigenetic alterations, including DNA
methylation and histone post-translational modiﬁcations, affecting TNBCs. Due to the promising results in preclinical studies, histone deacetylase inhibitors (HDACi) are currently being tested in several clinical trials for
breast cancer and other solid tumors. However, the genome-wide epigenetic and transcriptomic implications
of HDAC inhibition are still poorly understood. Here, we provide detailed information about the design of a
multi-platform dataset that describes the epigenomic and transcriptomic effects of HDACi. This dataset includes
genome-wide chromatin accessibility (assessed by ATAC-Sequencing), DNA methylation (assessed by Illumina
HM450K BeadChip) and gene expression (assessed by RNA-Sequencing) analyses before and after HDACi treatment of HCC1806 and MDA-MB-231, two human TNBC cell lines with basal-like phenotype.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Direct link to deposited data
Speciﬁcations
Organism/cell
line/tissue

Homo sapiens/cancer cell lines (HCC1806 and MDA-MB-231)

Sex
Sequencer or
array type
Data format

Female
- Illumina HiSeq 2500
- Illumina HumanMethylation450 BeadChip
Raw (FASTQ) and analyzed (BigWig) for ATAC sequencing data
Raw (FASTQ) and analyzed (TXT) for RNA sequencing data
Raw (IDAT) and analyzed (TXT) for DNA methylation arrays data
Human triple-negative cell lines treated with HDAC inhibitor
(LBH589)
HCC1806 and MDA-MB-231 treated with 10 nM of LBH589 for
28 days
N/A
N/A

Experimental
factors
Experimental
features
Consent
Sample source
location

⁎ Corresponding author at: Department of Translational Molecular Medicine, John
Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA.
E-mail address: marzesed@jwci.org (D.M. Marzese).
1
These authors (MAB and MPS) contributed equally to this work.

Study SuperSeries (GSE92911) Access:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
mlodeuqanxslvmz&acc=GSE92911
ATAC-Sequencing SubSeries (GSE92898) Access: https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?token=qjudwycgtfsfnuv&acc=
GSE92898
RNA-Sequencing SubSeries (GSE92910) Access:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
svsnwcgivzudﬁf&acc=GSE92910
DNA methylation SubSeries (GSE92909) Access:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
grgxqoouphyjhmz&acc=GSE92909
2. Experimental design and cell culture conditions
HCC1806 (cat#CRL-2335; ATCC, Manassas, VA) and MDA-MB-231
(cat#HTB-26; ATCC, Manassas, VA) cells were cultured in RPMI 1640
supplemented with 10 mM HEPES, 10% heat-inactivated fetal bovine
serum (FBS) and 1% penicillin-streptomycin (complete medium)

http://dx.doi.org/10.1016/j.gdata.2017.01.002
2213-5960/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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containing 10 nM of LBH589 (Panobinostat; cat#S1030; Selleck
Chemicals, Houston, TX) during 120 h followed by 48 h of incubation
in RPMI-1640 medium alone. To maintain the drug concentration, the
medium was refreshed every 24 h. This cycle was repeated 4 times to
complete 28 days of treatment. In parallel, HCC1806 and MDA-MB231 cells were cultured in complete medium containing drug vehicle
(DMSO) alone for the same period of time (28 days). RNA-Sequencing
(RNA-Seq), Assay for Transposase-Accessible Chromatin Sequencing
(ATAC-Seq), and DNA methylation arrays were performed after the 4 cycles. Finally, to evaluate the stability of HDACi-induced epigenetic
reprogramming, HCC1806 and MDA-MB-231 treated during 28 days
with 10 nM of LBH589 were cultured in complete medium alone for
14 additional days, and ATAC-Seq was performed. Gene expression
and DNA methylation proﬁling were also performed after the initial
96 h of incubation to evaluate early response to 10 nM of LBH589. A description of the cell lines analyzed, the regimens used and the data analyses performed are summarized in Table 1.
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5. RNA sequencing (RNA-Seq)
Total RNA from HCC1806 and MDA-MB-231 cells was extracted
using ZR-Duet DNA/RNA MiniPrep Plus (cat# D7003; Zymo Research,
Irvine, CA). RNA samples with high quality (RIN ≥ 8.0) and high purity
(OD 260/280 = 1.8–2.0) scores were used to generate libraries using
the Illumina TruSeq RNA Sample Preparation Kit v2 (Illumina Inc., San
Diego, CA). The mRNA libraries were sequenced on the Illumina HiSeq
2500 in Rapid Mode using 101 bp paired-end reads at the JWCI Sequencing Center [6].
6. RNA-Seq data processing
Base calling and de-multiplexing were processed using CASAVA v1.8
(Illumina Inc., San Diego, CA), reads were mapped to the GENCODE release 19 reference using STAR version 2.4.2a [7], and read counts were
generated using the –quantMode GeneCounts option in STAR. The
Bioconductor package DESeq2 was used to detect fold change differences in expression between conditions.

3. Assay for Transposase-accessible chromatin sequencing (ATAC-Seq)
7. DNA methylation proﬁling (HM450K)
ATAC-Seq was performed as previously described by Buenrostro
et al. [1]. Brieﬂy, 50,000 cells were washed in 50 μl cold PBS and
resuspended in 50 μl cold lysis buffer [1]. The nuclei were centrifuged
at 500 x g for 10 min at 4 °C. The pellet was then incubated with
transposition reaction mix for 30 min at 37 °C and then puriﬁed
using the MinElute PCR Puriﬁcation kit (Qiagen, Hilden, Germany).
The eluted transposed DNA was barcoded and ampliﬁed for 5 cycles,
and then 5 μl of the product was used for a qPCR side-reaction to
prevent ampliﬁcation saturation. The optimal amount of additional
PCR cycles was determined based on the number of cycles that represented one-third of maximum ﬂuorescence intensity in the qPCR
reaction after 20 cycles. The ﬁnal transposed DNA was ampliﬁed for
a total of 9–11 cycles. The ﬁnal ampliﬁed library was puriﬁed using
MinElute PCR Puriﬁcation kit and eluted in 20ul elution buffer. The
ATAC libraries were sequenced on the Illumina HiSeq 2500 in Rapid
Mode using 50 bp paired-end at the John Wayne Cancer Institute
(JWCI) Sequencing Center.

4. ATAC-Seq data processing
Raw genomic sequence reads were mapped to the 1000 Genomes
(b37) build of the human genome reference using BWA-MEM (version
0.7.5a) with default settings [2]. Alignments were further processed
using GATK (version 2.8–1) [3] for INDEL realignment and PicardTools
for duplicate marking (version 1.103) (http://broadinstitute.github.io/
picard/). ATAC-Seq peaks were identiﬁed using the callpeaks function
in MACS2 [4] with a threshold set to -q = 0.01. The resulting peak
calls were ﬁltered for sequences that mapped to the mitochondria
using shell scripts, and BigWig ﬁles were generated using
bedGraphToBigWig [5].

Genomic DNA was extracted from HCC1806 and MDA-MB-231 cells
using the Quick-gDNA MiniPrep kit (cat# D3025; Zymo Research,
Irvine, CA). Following, 1 μg of DNA was sodium bisulﬁte modiﬁed
(SBM) using the EZ DNA Methylation-Direct kit (cat# D5021; Zymo
Research, Irvine, CA). 200 ng of SBM-DNA was whole-genome
ampliﬁed, enzymatically fragmented and hybridized on the
HumanMethylation450 (HM450K) BeadChip (Illumina Inc., San Diego,
CA). The chips were scanned with Illumina iScan (Illumina, Inc., San
Diego, CA), as we previously described [8–11].
8. DNA methylation data processing
Data was extracted using the R package methylumi. The ‘noob’ function in the R package minﬁ was used to process the data and then the
‘dasen’ function in the R package wateRmelon for normalization and
dye-bias correction. DNA methylation levels were reported as β-value
(β = intensity of the methylated allele/(intensity of the unmethylated
allele + intensity of the methylated allele)) and calculated using the signal intensity value for each CpG site.
9. Discussion
In this article, we described a dataset involving transcriptomic and
epigenomic analysis of TNBC cells that were exposed for a prolonged
time to low doses of a clinically-approved HDACi. While the functional
consequences of this treatment approach remains to be elucidated in
the future, this multi-platform evaluation provides an opportunity to
deeply understand the genome-wide effects of this powerful epigenetic
drug and to identify novel transcriptomic and epigenomic clinically-relevant targets for TNBC tumors.

Table 1
Summary of the data analyses included in the dataset.
Name

Treatment

ATAC-Seq

HM450K

RNA-Seq

HCC1806-DMSO-96hs
HCC1806-LB-96hs
HCC1806-DMSO-4w
HCC1806-LB-4w
HCC1806-LB-4w + complete medium-2w
MDA-MB-231-DMSO-96hs
MDA-MB-231-LB-96hs
MDA-MB-231-DMSO-4w
MDA-MB-231-LB-4w
MDA-MB-231-LB-4w + complete medium-2w

DMSO for 96 h
LBH589 (10 nM) for 96 h
DMSO for 28 days
LBH589 (10 nM) for 28 days
LBH589 (10 nM) for 28 days + complete medium for 14 days
DMSO for 96 h
LBH589 (10 nM) for 96 h
DMSO for 28 days
LBH589 (10 nM) for 28 days
LBH589 (10 nM) for 28 days + complete medium for 14 days

x
x
✓
✓
✓
x
x
✓
✓
✓

x
✓
✓
✓
x
x
✓
✓
✓
x

✓
✓
✓
✓
x
✓
✓
✓
✓
x
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